People channel feed

Alex­ion chief reg­is­ters $16.5M in pay af­ter a sol­id year, with a rel­a­tive­ly low 74-to-1 ra­tio com­pared to a well paid staff

7 years ago

Al­ler­gan chief Brent Saun­ders bows to ac­tivists, but Ap­paloosa blasts back that it's all too lit­tle, too late

7 years ago
Deals

Af­ter land­ing a his­toric FDA OK, Al­ny­lam chief John Maraganore scores a big raise

7 years ago

Lit­tle Cona­tus' No­var­tis-part­nered liv­er drug suf­fers third straight de­feat, but CEO Men­to is still hold­ing out hope

7 years ago
R&D

$757M and 5 years lat­er, Cel­gene aban­doned a biotech part­ner, trig­ger­ing lay­offs

7 years ago
R&D

Found­ing For­ma CEO Steve Tre­gay fol­lows 61 staffers out the ex­it, re­placed by Genen­tech strat­e­gy vet

7 years ago

Is a new CEO in the cards at Sanofi as suc­ces­sion plan­ning heats up for top team?

7 years ago

Gilead CEO Mil­li­gan capped a rocky year — and his ca­reer — with the new #1 com­pen­sa­tion pack­age in the big leagues of bio­phar­ma

7 years ago

Des­per­ate­ly seek­ing a turn­around, be­lea­guered vet­er­an fund man­ag­er Wood­ford hits out at crit­ics, fake news

7 years ago

Ian Read bags $19.5 mil­lion, tak­ing a big pay cut for his swan song as Pfiz­er CEO and leav­ing the phar­ma gi­ant at a cross­roads

7 years ago

J&J chief Alex Gorsky suf­fers a big drop in com­pen­sa­tion, but still comes out way ahead of most ma­jor league CEOs

7 years ago

CEO of biotech in­vestor Her­cules Cap­i­tal aban­dons his post in the midst of a col­lege cheat­ing scan­dal

7 years ago
Financing

No­var­tis' San­doz chief is walk­ing out in the mid­dle of a glob­al re­vamp, fu­el­ing fresh buzz about a spin­off

7 years ago

Em­ma Walm­s­ley earns £1M pay rise in her first full year at GSK's helm — but £5.9M pack­age still trails oth­er Big Phar­ma CEOs

7 years ago

End­points News poll: In­dus­try in­sid­ers of­fer a big 👍 for Ned Sharp­less

7 years ago
Pharma

NCI's Ned Sharp­less gets the nod to run the FDA in wake of Scott Got­tlieb’s sur­prise ex­it

7 years ago
Pharma

Two big phar­ma ex­ecs share the same chal­lenges, but com­pen­sa­tion? They’re not even close

7 years ago

Prison of­fi­cials launch a probe in­to Mar­tin Shkre­li's lat­est an­tics, al­leged­ly run­ning his biotech busi­ness with a con­tra­band cell phone

7 years ago

The Fort Dix re­demp­tion: Mar­tin Shkre­li’s con­tra­band cell phones, new biotech schemes and fresh so­cial me­dia in­famy

7 years ago

From din­ner in Mu­nich to $5.85 a share, Im­mune De­sign ex­ecs pushed for every pen­ny they could get from the Mer­ck bar­gain buy­out

7 years ago
Deals

On­col­o­gy pipeline chief Alessan­dro Ri­va joins the ex­o­dus at Gilead, head­ing to helm a biotech spin­off 4 days af­ter O'­Day's ar­rival as CEO

7 years ago

Pop­u­lar FDA com­mish Scott Got­tlieb has hand­ed in his res­ig­na­tion

7 years ago
Pharma

Was As­traZeneca CEO Pas­cal So­ri­ot hap­py with his $14.8M in '18 com­pen­sa­tion? Prob­a­bly not so much

7 years ago

Bad year at Cel­gene? For­get about it. CEO Mark Alles nabbed a big raise as com­pen­sa­tion gy­rat­ed to $16.2M

7 years ago
First page Previous page 80818283848586 Next page Last page
A service from the Financial Times